Taking strides in vaccine development

Science

Currently the production of vaccines takes place in small silos, it is this area where there is possibility for enhancement. Seeing the overall process and digitalizing the value chain would create noteworthy improvement.

GSK, ATOS and Siemens worked together to create a new, innovative idea called digital twin. This uses both the real and digital worlds in conjunction with each other in a closed loop.

“This uses both the real and digital worlds in conjunction with each other in a closed loop“

The three companies have made a digital twin explicitly for the engineering of adjuvant (vaccine ingredients that help immune response) technologies which can aid those individuals with vulnerable immune systems. These additives decrease the amount of antigen needed in vaccine doses, therefore helping to create a larger supply of vaccines when demand peaks.

Reproduction of the vaccine additive’s particles usually takes a long time (multiple hours), therefore the companies working on the project removed the need for this lengthy procedure and instead replicated it using CFD (computational flow dynamics). This meant that they will produce and save imitation records for cases up front. This ability alongside statistical trial planning data and machine learning allows them to estimate which adjuvants’ particles will be produced with each variation in critical limits.

It’s now conceivable to gather data and have a comprehensive view of what is going on in real time during vaccine production with digital twins. It enables monitoring of complicated procedures and forecast how changes may impact them.

The next move for GSK is working alongside Siemens to develop and introduce

digital twins that work for the whole manufacturing process for vaccines.

See all the latest jobs in Science
Return to news